Dupont Capital Management Corp bought a new position in shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 27,334 shares of the specialty pharmaceutical company’s stock, valued at approximately $661,000. Dupont Capital Management Corp owned 0.09% of Flexion Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its stake in shares of Flexion Therapeutics by 27.9% during the second quarter. Bank of New York Mellon Corp now owns 2,716,189 shares of the specialty pharmaceutical company’s stock worth $54,921,000 after buying an additional 591,981 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Flexion Therapeutics by 32.4% during the second quarter. Janney Montgomery Scott LLC now owns 17,970 shares of the specialty pharmaceutical company’s stock worth $363,000 after buying an additional 4,395 shares during the period. Teachers Advisors LLC increased its stake in shares of Flexion Therapeutics by 3.1% during the first quarter. Teachers Advisors LLC now owns 44,796 shares of the specialty pharmaceutical company’s stock worth $1,205,000 after buying an additional 1,328 shares during the period. Scholtz & Company LLC purchased a new stake in shares of Flexion Therapeutics during the second quarter worth approximately $1,131,000. Finally, Wells Fargo & Company MN increased its stake in shares of Flexion Therapeutics by 37.4% during the second quarter. Wells Fargo & Company MN now owns 171,351 shares of the specialty pharmaceutical company’s stock worth $3,464,000 after buying an additional 46,634 shares during the period. Hedge funds and other institutional investors own 72.04% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Dupont Capital Management Corp Buys New Position in Flexion Therapeutics, Inc. (FLXN)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/12/dupont-capital-management-corp-buys-new-position-in-flexion-therapeutics-inc-flxn.html.

FLXN has been the topic of several recent analyst reports. Royal Bank Of Canada reiterated an “outperform” rating and issued a $44.00 price target on shares of Flexion Therapeutics in a research note on Thursday, August 10th. Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target (up from $34.00) on shares of Flexion Therapeutics in a research note on Thursday, August 10th. BMO Capital Markets reiterated a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. Finally, Northland Securities initiated coverage on shares of Flexion Therapeutics in a research note on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price target on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $98.33.

Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) opened at $23.99 on Friday. Flexion Therapeutics, Inc. has a fifty-two week low of $15.96 and a fifty-two week high of $32.25. The company has a debt-to-equity ratio of 0.87, a quick ratio of 18.29 and a current ratio of 12.93.

In other news, insider Michael D. Clayman acquired 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 8th. The stock was acquired at an average cost of $23.60 per share, with a total value of $118,000.00. Following the completion of the acquisition, the insider now owns 35,395 shares of the company’s stock, valued at $835,322. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Yamo Deniz acquired 1,375 shares of the firm’s stock in a transaction dated Thursday, August 31st. The stock was purchased at an average cost of $25.40 per share, with a total value of $34,925.00. Following the completion of the acquisition, the insider now directly owns 5,000 shares of the company’s stock, valued at approximately $127,000. The disclosure for this purchase can be found here. Insiders bought 10,375 shares of company stock valued at $249,575 over the last three months. Corporate insiders own 15.98% of the company’s stock.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics, Inc. (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.